GlaxoSmithKline and Innoviva announced the filing of a supplemental New Drug Application (sNDA) to the FDA seeking an additional indication...
GlaxoSmithKline plc and Innoviva, Inc. announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’)...
GlaxoSmithKline and Innoviva announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy...
GlaxoSmithKline and Innoviva announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, one...
GlaxoSmithKline plc and Innoviva, Inc. announced the FDA has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD).
GlaxoSmithKline and Innoviva announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, FF/UMEC/VI)...
GlaxoSmithKline plc and Innoviva, Inc. announced that the FDA has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under...
GlaxoSmithKline plc and Innoviva, Inc. announced the filing of a supplemental New Drug Application (sNDA) with the FDA for the...